RCMT · RCM Technologies, Inc.

RCM Technologies delivered strong fiscal 2025 results with full-year revenue reaching $319.4 million, a 14.7% increase from $278.4 million in the prior year, driven by growth across Specialty Health Care (up to $164.1 million), Engineering ($120.5 million), and Life Sciences, Data and Solutions ($34.8 million) segments. The fourteen-week Q4 showed revenue of $86.5 million, up 12.4% year-over-year, with gross profit expanding 12.6% to $24.3 million and gross margin stable at 28.1%. GAAP operating income rose to $8.0 million in Q4 from $6.3 million prior year, supported by lower SG&A as a percentage of revenue and absence of prior-year impairment and remeasurement charges. Full-year GAAP net income increased 22.6% to $16.3 million, with diluted EPS at $2.14 versus $1.68. Adjusted EBITDA grew significantly, up 49.0% to $9.3 million in Q4 and 18.9% to $30.7 million for the year, reflecting operational leverage from equity compensation normalization and other adjustments. Segment gross margins varied: Specialty Health Care at 29.0% in Q4 (down slightly from 30.6%), Engineering improved to 25.6% from 19.7%, and Life Sciences at 31.6% versus 40.0%. Balance sheet reflects reduced debt with line of credit borrowings down to $24.7 million from $35.0 million, cash at $2.9 million, and strengthened equity to $46.0 million from $33.5 million, aided by accumulated deficit turning positive to $10.4 million. No conference call was held, with further details in the upcoming Form 10-K. Forward-looking statements highlight risks but no specific guidance provided.